Jun 19, 2004|
Global markets: Lackluster week
Profit booking among tech stocks clipped nearly 1% off the Nasdaq during the week ended June 18, 2004. Dow, on the other hand remained almost unchanged, thanks largely to gains in select blue chips.
With both the benchmark indices showing divergent trends, there have been talks about the possibility of re-emergence of sector rotation strategy, whereby investors seem to be rotating their money from seemingly overheated tech stocks into defensive, high dividend paying sectors like industrials and transport, probably in anticipation of higher interest rates. A profit warning earlier in the week from a not so active Nasdaq component called Jabil Circuit gave investors an excuse to book profits in the tech laden Nasdaq and might have also led to weakness in the same. While low volumes has remained a bane in the markets for quite some weeks now, it is widely expected that the earnings season due next month would help bring back investors in droves.
Major indices across Asia largely remained in the throes of profit booking and closely followed their US counterpart. While investors did take some solace from Fed chairman's testimony earlier in the week, weakness in tech stocks at the fag end of the week largely contributed to the decline among Japanese and Hong Kong indices. Elsewhere in the European markets, gains in UK's top grocer Tesco on Friday helped mask the effect of declines in couple of heavyweights and resulted into the benchmark FTSE ending marginally higher for the week. Lack of volumes and absence of any significant growth trigger continued to haunt the Indian benchmark as it further edged lower by 1%.
|(Price in US$)
Barring a couple of software majors, Indian ADRs experienced weakness on the US bourses during the week. Selling pressure was particularly stronger among dotcom ADRs and ILD major, VSNL, which along with Rediff, lost 9% and emerged as the highest losers. Pharma major Dr Reddy continued to experience decline in its fortunes and lost almost 5% during the week. The stock shed 6% on the Indian bourses presumably on the back of a report that claimed that the size of the US generic markets was largely overstated and due to imminent competition, the margins might also come under pressure. A big negative for companies like Dr Reddy that derives a significant part of its revenues from the US markets. On account of lack of buying opportunity elsewhere, software ADRs continued to remain in the good books of investors and were the lone gainers on the US bourses. Satyam however, bucked the trend and lost nearly 4% over the week.
More Views on News
Jul 25, 2017
Equitymaster HQ has been infiltrated. Valuable stock ideas have been leaked. Who's responsible?
May 27, 2017
What happens when minority shareholders are short-changed in the normal course of business?
Feb 15, 2017
PersonalFN believes SEBI has taken a step back-apparently in the admission of it going overboard with the regulations.
Aug 24, 2016
And here's your chance to claim a free copy of this book...
Aug 12, 2016
And Why India's demographic dividend could turn out to be a doubtful debt...
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407